The World Dementia Council has 24 members working across six continents. Council members are global leaders who work in research, academia, industry and civil society. They attend meetings, vote on key issues and participate in the organisation's work. The council also includes members who are living with dementia.

The Council also has multiple associate members consisting of international organizations as well as national governments. They help to ensure that the council's agenda aligns with other global dementia initiatives, providing the council with important strategic advice, guidance and intelligence. As they do not have full membership status, associate members don't vote on issues such as the election of a new chair or new members, or on matters of governance.

  • Professor Philip Scheltens
    Professor Philip Scheltens
    Chair, Trustee and Member

    Professor Dr Philip Scheltens studied at the VU University Amsterdam, Netherlands, gaining his MD in 1984, and PhD in 1993. He became Professor of Cognitive Neurology and founder of the Alzheimer Center at Amsterdam University Medical Centers in 2000, which he directed until 2022. Currently he devotes most of time heading the Dementia Fund at EQT Life Sciences, that he started in 2020.

    He has been the (inter)national PI for over 35 studies, including phase 1-3 multicenter clinical trials. He supervised >75 PhD theses since 2000. He founded the Dutch national plan against dementia and served as chair of the board. He is co-editor-in-chief of Alzheimer’s Research & Therapy and co-leads various EU projects. He authored over 1100 peer reviewed papers and > 75 book chapters and co-edited several major text books.

    He is member of the Royal Dutch Academy of Arts and Sciences (KNAW) since 2011. In 2016 he was awarded the European Grand Prix for Alzheimer’s Research. In 2020 he was Knighted in the Order of the Netherlands Lion by the King of the Netherlands. In 2021 he was elected honorary member of the European Academy of Neurology and was appointed chair of the World Dementia Council.

  • Professor Kiyoshi Kurokawa
    Professor Kiyoshi Kurokawa
    Vice chair, Trustee and Member

    Professor Kiyoshi Kurokawa is Chair, Health and Global Policy Institute; Professor, Emeritus of the University of Tokyo and National Graduate Institute for Policy Studies; Distinguished Research Affiliate, The MIT Media Lab; and Chair and Representative Director, Global Health Innovative Technology Fund.

    Dr. Kurokawa is well known internationally in the fields of medicine, health, science, technology and innovation policies through his leadership, including as President of the Science Council of Japan and Science Adviser to the Prime Minister and WHO Commissioner. He was professor at UCLA School of Medicine, Tokyo University and Dean of Tokai University School of Medicine. He has received many awards, including the AAAS Scientific Freedom and Responsibility award and a 100 Top Global Thinkers award for his leadership in the National Diet of Japan Fukushima Nuclear Accident Independent Investigation Commission.

  • Professor Ricardo Allegri
    Professor Ricardo Allegri
    Trustee and Member

    Professor Ricardo F. Allegri is Head of the Department of Cognitive Neurology, Neuropsychiatry and Neuropsychology and Director of the Ageing and Memory Centre at the Neurological Research Institute Raúl Carrea (FLENI) in Buenos Aires. He is also Professor of Neurology in the School of Medicine at the University of Buenos Aires and is chair of the Scientific Council at the Association against Alzheimer's disease and related disorders in Argentina (ALMA).

    Professor Allegri has published extensively on cognitive neurology in neurological journals and books and has co-edited seven books, including, “Dementia: A Multidisciplinary Approach,” one of the most important books written in Spanish on this topic. He has received over 45 awards in the field of Cognitive Neurology and Neuropsychiatry, including the National Academy of Medicine Award in 2006 and the Research Recognition Award by the School of Medicine, University of Buenos Aires in 2014.

  • Professor Philippe Amouyel
    Professor Philippe Amouyel

    Professor Philippe Amouyel is General Director of Fondation Plan Alzheimer and Professor of Epidemiology and Public Health at the University Hospital of Lille, France. Since 1998, Professor Amouyel has headed a research unit of 50 people dedicated to public health and the molecular epidemiology of age-related diseases. He has published more than 750 scientific articles and participated in the discovery of 20 confirmed genetic loci predisposing to sporadic Alzheimer’s disease.

    At the European level, Professor Amouyel also chairs the European Joint Programming Initiative on research on neurodegenerative diseases and Alzheimer’s in particular (JPND). The main objective of JPND is to combine the strength of European and global research to tackle these diseases more efficiently.

  • Paola Barbarino
    Paola Barbarino

    Paola Barbarino is the CEO of Alzheimer’s Disease International. Prior to that, she was CEO of LIFE. Her previous senior positions include Cass Business School, Tate, British Library and IIED.

    She is a Trustee of The Postal Museum and Lauderdale House. Previously she was a Trustee of Shelter, the UK housing and homelessness charity and of MLA London. She is also the Managing Director of Opaline Limited, a consultancy company specializing in strategy and governance.

     She holds a degree cum laude in Classics from the University of Napoli Federico II, an MA in Field and Analytical Techniques in Archaeology and an MA in Library and Information Science both from University College London.

  • Professor Howard Bergman
    Professor Howard Bergman

    Dr Howard Bergman, Assistant Dean for International Affairs, is Professor in the departments of Family Medicine, Medicine and Oncology as well as in the Institute for Health and Social Policy of the School of Population and Global Health at the McGill University Faculty of Medicine and Health Sciences. He is a Fellow of the Canadian Academy of Health Sciences (CAHS) and a Fellow of both the College of Family Physicians of Canada and the Royal College of Physicians and Surgeons of Canada. He was the inaugural Dr Joseph Kaufmann Chair in Geriatric Medicine (2001-2015) and Chair of the Department of Family Medicine (2012-2019). Dr. Bergman is recognized for his research which has influenced policy change in primary care, aging and dementia. As part of a government independent commission (2000), Dr. Bergman was the lead on a major reform of primary medical care creating team based Family Medicine Groups. He is author of the Quebec Alzheimer Plan (2009) working with government on its implementation. He co-leads the Canadian team for healthcare services/system improvement in dementia care (ROSA research team). In 2019, at the request of Public Health Agency of Canada, he chaired the CAHS Expert Panel for the Assessment of Evidence and Best Practices for the development of the Canadian Dementia Strategy. Dr. Bergman is a member of the Board of Directors of the Quebec Institut national d'excellence en santé et en services sociaux.

  • Professor Paulo Caramelli
    Professor Paulo Caramelli

    Paulo Caramelli obtained his MD in 1987 at the University of São Paulo (USP) School of Medicine, in São Paulo, Brazil and completed the residency program in Neurology at the Hospital das Clínicas of the USP School of Medicine in 1991. Research fellow at the University of Montréal, Canada, from 1992 to 1994. In 1997, he completed a PhD in Neurological Sciences at the USP School of Medicine. He is currently Professor of Neurology at the Faculty of Medicine of the Federal University of Minas Gerais (UFMG) and Coordinator of the Behavioral and Cognitive Neurology Research Group at UFMG, in Belo Horizonte, Brazil, where he also supervises MSc and PhD students. Vice chair (2021-2022) and chair-elect (2022-2024) of the Advisory Council of ISTAART (Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment). Editor-in-chief of Arquivos de Neuro-Psiquiatria. Associate editor of the American Journal of Neurodegenerative Disease, eNeurologicalSci and Journal of Alzheimer's Disease. His research activities are focused on clinical, epidemiological and translational studies on cognitive impairment and dementia, particularly Alzheimer’s disease and frontotemporal dementia, including studies investigating education and cognitive reserve in the older adult population.

  • Arthena Caston
    Arthena Caston

    Arthena Caston was diagnosed with MCI in 2016. Prior to her diagnosis, Arthena was working in customer support for a large insurance company when she began noticing lapses in her memory. At home, Arthena found favorite pursuits, including reading, cooking, and routine trips to the craft store were becoming more challenging.

    Prompted by her worsening memory lapses, Arthena and her husband, Virous, shared their concerns with her primary care physician. After two years of visits to various specialists, Arthena received her diagnosis of MCI at the age of 51.

    After a period of reckoning with the news and “feeling numb,” Arthena has regained a sense of purpose and passion for sharing what life is like living with MCI through volunteering and sharing her story. Arthena wants to encourage disease education and the importance of having conversations early when cognitive changes first appear. She also hopes to encourage others to live well with the disease.

    Arthena was appointed to the board of her local Georgia Alzheimer’s Association chapter and was selected to serve as a member of the Association’s National Early-Stage Advisory Group during the 2019-202 term. Arthena is currently a member of the Alzheimer’s Association’s national governing board.

    Arthena and her husband, Virous, live in Macon, Georgia with their two dogs. They have two adult daughters serving in the U.S. Air Force, and three grandchildren.

  • Hilary Evans
    Hilary Evans

    Hilary Evans is Chief Executive of Alzheimer’s Research UK (ARUK), the UK’s leading dementia research charity. ARUK is committed to investigating the causes of dementia and developing ways to prevent, diagnose, treat and, ultimately, cure all forms of the condition. As Chief Executive since 2015, Hilary has led the transformation of the charity to one of the leading medical research charities in the UK.  She has overseen a significant growth in income in recent years, with ARUK being one of the fastest growing UK charities. This growth has significantly enhanced the organisation’s ability to fund new innovative projects, particularly those that unite charity, academic and private sectors in the search for new dementia treatments. Hilary is driven and fascinated by ideas that can make a difference and has led major public campaigns to change public perceptions of dementia and break down the stigma around these diseases. Before joining Alzheimer’s Research UK Hilary worked at Age UK, improving the lives of people in later life both in the UK and internationally. She also brings experience of working in Government and with the pharmaceutical industry. Hilary is a Trustee of the Association of Medical Research Charities and holds an honorary doctorate in medicine from The University of Exeter.

  • Phyllis Ferrell
    Phyllis Barkman Ferrell

    Phyllis Ferrell is the Global Head of External Engagement for Alzheimer’s disease and Neurodegeneration at Eli Lilly & Company, where she previously served as the leader of the Global Alzheimer’s disease development team.  Ferrell’s most recent prior position was Vice President of the Chief Commercial Services Officer for Eli Lilly and Company.

    Ferrell has been with Lilly for more than 25 years and has held many leadership roles throughout the organization. She has led efforts in medical affairs, medical development, commercial capabilities, sales, marketing, recruiting, business development, strategy, transformation, Six Sigma, and corporate financial planning.  

    Ferrell received a Bachelor of Arts degree in economics and management with minors in computational mathematics and Asian studies from DePauw University.  She graduated Phi Beta Kappa and with Magna Cum Laude honors in 1994.  She received an MBA in general management and a certificate in public management from the Stanford University Graduate School of Business in 2001 and graduated with both Arjay Miller Scholar honors and as the Arbuckle Award recipient.

    Phyllis was recognized with the Rising Star Award from the Healthcare Businesswomen’s Association and the Indianapolis Star Top 40 Under 40.  Phyllis is a current member of the World Dementia Council, a steering committee member of the Milken Institute Center for Aging Alliance for Dementia Care and NMQF Alzheimer’s Disease Index working groups, and a strategic reviewer for the Alzheimer’s Disease Drug Discovery Foundation and Gates Ventures Diagnostics Accelerator.  She is also a member of the Indiana Chapter of the Healthcare Businesswomen’s Association; on the Boards of Directors for Alzheimer’s Research UK EDoN, the Indiana Chapter of the Alzheimer’s Association, Stanford Associate Board of Governors, Indianapolis 500 Festival, and the Lebanon Area Boys & Girls Club. Phyllis is a founding member of Women Against Alzheimer’s and Women of Impact Boone County; co-chair of the Women’s Leadership Council; the alumna sponsor of the Women in Economics and Business Program at DePauw University; a member of the Washington C. DePauw Society; a Tocqueville donor to United Way; an active supporter of Boone County Special Olympics and the Boone County Community Foundation; and a coach’s wife and mother of two very active boys (ages 18 and 14).

  • Dr Margaret Hamburg
    Dr Margaret Hamburg

    Dr Margaret A. Hamburg is an internationally recognized leader in public health and medicine. Dr Hamburg just completed her term as Foreign Secretary of the National Academy of Medicine, where she served as senior advisor on international matters and liaison with other Academies of Medicine around the world. She is also the immediate past Chair/President of the American Association for the Advancement of Science (AAAS), the world’s largest scientific membership organization.

    Dr Hamburg is a former Commissioner of the U.S. Food and Drug Administration (FDA), where she was known for advancing regulatory science, modernizing regulatory pathways, and globalization of the agency. Other positions have included: Assistant Secretary for Planning and Evaluation, HHS; VP and Chief Scientist Nuclear Threat Initiative: NYC Heath Commissioner; Assistant Director, National Institute of Allergy and Infectious Diseases, NIH. She currently sits on a number of Boards, including the Lasker Foundation, Commonwealth Fund, the Simons Foundation, the Council on Foreign Relations, the Global Alliance for Vaccines (GAVI) and Alnylam Pharmaceuticals among others. Dr. Hamburg is a graduate of Harvard College and Harvard Medical School. She is widely published and has received numerous awards and honorary degrees.

  • Paul Hogan
    Paul Hogan

    Paul Hogan founded Home Instead Senior Care® with his wife Lori in 1994. Today, the franchise network is the world's leading provider of home care services for seniors, with more than 1,100 independently owned and operated offices that provide more than 60 million hours of care annually across 12 countries on four continents. In addition to his work with the World Dementia Council, Hogan serves on the Board of Governors for the Global Health and Healthcare Partnership Community at the World Economic Forum (WEF) and had previously served as the Vice Chair for the Global Agenda Council on Ageing.

  • Harry Johns
    Harry Johns
    Trustee and member

    Harry Johns is the CEO of the Alzheimer's Association. The Association, working with leading members of the U.S. Congress, has achieved significant public policy advances in care, support, and health infrastructure, as well as increasing federal research investments from just $450 million to $3.2 billion annually. The Association's global leadership in research includes $255 million currently at work in 48 countries, and breakthroughs that have changed the trajectory of dementia research, including facilitation of crucial diagnostics and the first class of treatments for the biology of Alzheimer's. Harry and his wife Cindy have faced Alzheimer's with their mothers.

  • Brian
    Professor Brian Lawlor

    Professor Brian Lawlor is Professor of Old Age Psychiatry at Trinity College Dublin and Deputy Executive Director of the Global Brain Health Institute based at Trinity College Dublin and University of California San Francisco. His main clinical and research interests are in the diagnosis and treatment of Alzheimer’s disease, behavioural and psychological symptoms of dementia and on the impact of  loneliness on the brain health and wellbeing of older people. As a psychiatrist, he has been involved in the care of people with dementia for over 30 years. He was the founding director of the Memory Clinic at St. James’s Hospital, Dublin and Chair of the Irish National Dementia Awareness Campaign.   

  • Maryna Lehmann
    Maryna Lehmann

    Maryna Lehmann was diagnosed with dementia in February 2018 at the age of 58, and lives in George, South Africa. She was born in Johannesburg, South Africa, in 1960. She is the eldest of 5 siblings and matriculated in 1977. She enrolled for a BSc (Agric.) at Pretoria University and completed the Honours Degree in 1981. She married the same year. Her husband, André, retired in February 2019 to take care of her.

    In January 1982 she was employed as a farm manager of 300 sow piggery, 400 extensive cattle, 3000 head in feedlot. In the next 18 years she reared 4 sons and taught in numerous agriculture schools. On 1 January 2000 she joined Nelson Mandela University, as the Animal Science lecturer and completed a Masters Degree in Animal Science. She received numerous accolades such as upcoming researcher and upcoming teacher in 2006 and also received the "overall" teacher of the year award in 2007.

  • Chris Llewellyn
    Chris Llewellyn
    Trustee and Member

    Chris Llewellyn is a Senior Partner at McKinsey & Company, based in London. A physician by background, he has extensive knowledge and experience in healthcare. He is the Head of McKinsey’s Medical Products practice in EMEA and Global Leader of the Life Science Practice.

    Chris Llewellyn has worked with the President of Israel to plan a world-leading neurotechnology cluster and helped the then UK Prime Minister, David Cameron to develop a national life sciences strategy focusing on attracting investment and boosting employment in the sector and beyond.

  • Dr Husseini Manji
    Dr Husseini Manji

    Husseini K Manji, MD, FRCPC is Global Head, J&J Science for Minds, and immediate past Therapeutic Head for Neuroscience at Janssen Research & Development, one of the Johnson & Johnson pharmaceutical companies. His research has investigated disease- and treatment-induced changes in gene and protein networks that regulate synaptic and neural plasticity in neuropsychiatric disorders. This has led to the FDA approval of the first novel antidepressant mechanism (NMDA-antagonism) in decades and has been actively involved in developing biomarkers to help refine these diseases. Dr Manji has been inducted into the National Academy of Medicine, the World Economic Forum Global Future Councils and is a member of Harvard/MIT’s Stanley Center SAB, amongst other appointments. He has received a number of awards including the NIMH Director's Career Award for Significant Scientific Achievement, and has published extensively on the molecular and cellular neurobiology of severe neuropsychiatric disorders and development of novel therapeutics with over 300 publications in peer-reviewed journals, including Science and Nature Neuroscience. He is an Honorary Fellow at Oxford University and Visiting Professor at Duke University, and previously served as Chief of the Laboratory of Molecular Pathophysiology at the NIH as well as Director of the NIH Mood and Anxiety Disorders Program, the largest program of its kind in the world.

  • Tetsuyuki (Tetsu) Maruyama, PhD
    Dr Tetsuyuki (Tetsu) Maruyama

    Dr Tetsu Maruyama is the Executive Director of the ADDI, where he has the pleasure of working with an exceptional team to enable data relevant to Alzheimer’s and related dementias to reach their full potential.

    Prior to joining ADDI, Tetsu was the Chief Scientific Officer at the Dementia Discovery Fund, a unique venture capital fund focusing a total investment of $350 million on creating new treatment paradigms for dementia. Before that he was head of Drug Discovery for Takeda Pharmaceuticals in Japan, after leading the GlaxoSmithKline Centre for Cognitive and Neurodegenerative Disorders in Singapore. He began his industry career at Merck Sharp and Dohme’s Neuroscience Research Center in the UK, after 15 years as an academic neuroscientist at Cardiff University and the University of Minnesota.

    Tetsu has contributed to the promotion of open science, having been Chairperson of the Board of the Structural Genomics Consortium from 2016 through 2020, and of being a member the Board of Directors of Sage Bionetworks. He is also on the Board of Directors or Scientific Advisory Board of a number of privately held biotech companies and is a member of the World Dementia Council. Tetsu received his PhD in behavioral neuroscience Stanford University and did post-doctoral research in neurophysiology at Yale University.

  • Meera Pattabiraman
    Meera Pattabiraman
    Trustee and Member

    Meera Pattabiraman, a postgraduate in business administration, entered the field of social work after she lost her father to Alzheimer’s disease and has been associated with the Alzheimer’s & Related Disorders Society of India (ARDSI) for over 24 years. She is currently President Emeritus of ARDSI after having served as Chair for ten years. She is one of the authors of the Dementia India Report 2010. The pioneering Kerala State Initiative on Dementia (KSID) was conceived in collaboration with two different state institutions namely, Social Justice Department of Kerala and Kerala Social Security Mission and rolled out in the year 2014 during her Chairmanship. Under her guidance, the Dementia India strategy report leading to a country plan was prepared. This report was handed over to the Health Ministers Sri. J P Nadda and Dr. Harsh Vardhan. It is to her credit that India is part of the prestigious research study ‘Strengthening Responses to Dementia in Developing Economies’. Meera took the lead to implement the Dementia Care Skills Programme across the country. She is a Board member of ADI and Chair of the Asia Pacific Regional office of ADI.

  • Lorna
    Lorna Sabbia

    Lorna Sabbia is a 26-year veteran with the firm and is currently Head of Retirement & Personal Wealth Solutions at Bank of America. She is responsible for both the institutional and personal retirement capability set to include 401(k), Equity and Health Benefit plans for companies of all sizes as well as college savings, personal retirement planning, retirement income, insurance and estate planning for individuals.

    Prior to this role, Lorna served as Head of Managed Solutions where she led the discretionary and non-discretionary fee-based investment platforms, the global mutual fund and ETF offerings across all channels, and relationship management with third-party investment partners. In addition, she drove the creation and implementation of Merrill Lynch One, the largest and most successful launch of an investment advisory platform in our firm’s history.

    Previous to this position, Lorna was Head of the Client Solutions Group, leading all Investments & Wealth Management and Wealth Structuring specialists and support desks, the Portfolio Strategies Desk, Annuity and Life Insurance Product management, in addition to the management of investment partner and insurance carrier relationships.

    Before joining the Client Solutions Group, Lorna was Head of Sales and Marketing for Merrill Lynch Trust Company (now part of Bank of America Private Bank), and from 2002 to 2006, she served as National Sales Manager for Merrill Lynch Investment Managers. She began her career at the company as a specialist for nearly eight years in two divisions, New York and New England, across three different disciplines.

    Lorna earned a Bachelor of Science degree in Business Administration from Boston University. She is a member of the firm’s management and operating committees, Executive Sponsor of the company’s Diverse Leader Sponsorship Program, Co- Chairs the firm’s Global Diversity & Inclusion Council, and serves as Market Sponsor for the Knoxville market. She is also Chair Emeritus for the Money Management Institute’s Board of Governors.

    Lorna is a member of the Women Against Alzheimer’s Leadership Council, the World Dementia Council, and board member for More Than Words, a Boston- based job training and youth development program. She also serves on the Executive Advisory Council of the Pat Summitt Leadership Group.

  • Professor Shekhar Saxena
    Professor Shekhar Saxena

    Dr Shekar Saxena is Professor of the Practice of Global Mental Health at Harvard T H Chan School of Public Health. He is a psychiatrist by training and has worked previously at World Health Organization for 20 years including as the Director of the Department of Mental Health and Substance Abuse, Geneva from 2010 to 2018. His expertise includes providing advice and technical assistance to policy makers on prevention and management of mental, developmental, neurological and substance use disorders and suicide prevention.  He led the WHO team for adoption of the first ever Mental Health Action Plan by the World Health Assembly in 2013. He also led the adoption of WHO Action Plan on Public Health Response to Dementia and its implementation.

  • George Vradenburg
    George Vradenburg
    Trustee and Member

    George Vradenburg convenes the Global CEO Initiative on Alzheimer’s (CEOi), a patient-centered industry coalition working with government, researchers and patients to develop and deliver innovative medicines to those touched by dementia and improve their quality of care. He also chairs the Global Alzheimer's Platform Foundation (GAP) and is chair and co-founder of USAgainstAlzheimer’s (USA2), which convenes CEOi and is a “disruptive,” entrepreneurial and patient-focused US based NGO committed to stopping Alzheimer’s disease by 2020.

    USA2 also founded and leads GAP, the North American arm of a global initiative to re-engineer Alzheimer's clinical trials for greater speed, efficiency, quality and diversity; and co-convenes Leaders Engaged on Alzheimer’s Disease, a US-based 90+ member coalition of Alzheimer’s-serving organisations mobilising a movement to end Alzheimer's. George Vradenburg is also a member of the Council on Foreign Relations and the Economic Club of Washington, DC. Before his retirement, he served in senior executive positions at AOL/Time Warner, Fox and CBS.

  • Professor Huali Wang
    Professor Huali Wang

    Dr Huali Wang is Professor and the Chair for Clinical Research, Director of the Dementia Care and Research Center, and Associate Director of Beijing Dementia Key Lab, Peking University Institute of Mental Health.

    She established the first dementia caregiver support group in China in 2000. Now she directs a training program for community doctors and service providers, and a train-the-trainer program for dementia caregivers support in China. She published five books on dementia care, including Smart Caregivers, China Memory Clinic Guideline and Practice Manual on Psychological Support for Older Adults. The care model has been partly adopted by WHO West Pacific Regional Office to develop the toolkit for community-based dementia care in low- and middle-income countries. Dr Wang is leading the National Platform on Clinical Dataset and Biobank of Major Mental Disorders. In regard to biomarker research of Alzheimer's Disease, she found that ApoE4 allele potentially modulates the hippocampal connectivity and the brain functional connectome.

    Huali also serves leading position in national and international mental health research and service advocacy, including Secretary of International Psychogeriatric Association, Vice President of Chinese Society of Geriatric Psychiatry (founding member), Executive Vice President of Alzheimer's Disease Chinese (member of ADI), and WHO Global Dementia Observatory Focal Point for China. Dr Wang obtained Bachelor of Medicine from Beijing Medical University in 1994, and MD/PhD from Peking University in 2001. She has also attended Harvard Medical School (2002, 2012), the University of California, Irvine (2002-2005), and Duke University (2013).

Associate governments

  • Australia
  • Canada
  • Japan
  • Mexico
  • Netherlands
  • UK
  • Our history

    The World Dementia Council (WDC) was created in February 2014, following the G8 Dementia Summit in London in December 2013.